564 656
[26]
Kuderer NM, Burton KA, Blau S, et al. Comparison of 2 commercially available next-generation sequencing platforms in oncology. JAMA Oncol 2017;3:996–8.[27]
Ko AH, Bekaii-Saab T, Van Ziffle J, et al. A multicenter, open-label phase II clinical trial of combined mek plus egfr inhibition for chemotherapy-refractory advanced pancreatic adenocarcinoma. Clin Cancer Res 2016;22:61.
[28]
Schwaederle M, Husain H, Fanta PT, et al. Use of liquid biopsies in clinical oncology: pilot experience in 168 patients. Clin Cancer Res 2016;22:5497–505.
[29]
Schwaederle M, Husain H, Fanta PT, et al. Detection rate of action- able mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget 2016;7:9707–17.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 5 5 7 – 5 6 4
564